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Abstract
Introduction: Increasing evidence supports a role of an epithelial to mesenchymal transition (EMT) process in endowing
subsets of tumor cells with properties driving malignant tumor progression and resistance to cancer therapy. To advance
our understanding of the underlying mechanisms, we sought to generate a transplantable cellular model system that allows
defined experimental manipulation and analysis of EMT in vitro and at the same time recapitulates oncogenic EMT in vivo.
Methodology/Results: We have established a stable murine breast cancer cell line (Py2T) from a breast tumor of an MMTV-
PyMT transgenic mouse. Py2T cells display a metastable epithelial phenotype characterized by concomitant expression of
luminal and basal cytokeratins and sheet migration. Exposure of Py2T cells to transforming growth factor b (TGFb) in vitro
induces reversible EMT accompanied by downregulation of E-cadherin and upregulation of mesenchymal markers,
including EMT transcription factors, and a gain in single cell motility and invasiveness. Py2T cells give rise to tumors after
orthotopic injection into syngeneic FVB/N mice. Notably, transplantation of epithelial Py2T cells results in the formation of
invasive primary tumors with low to absent E-cadherin expression, indicating that the cells undergo EMT-like changes
in vivo. This process appears to at least in part depend on TGFb signaling, since tumors formed by Py2T cells expressing
a dominant-negative version of TGFb receptor widely maintain their epithelial differentiation status.
Conclusions/Significance: Together, the data demonstrate that the Py2T cell line represents a versatile model system to
study the EMT process in vitro and in vivo. The observation that Py2T cells give rise to tumors and collectively undergo EMT-
like changes in vivo highlights the suitability of the Py2T model system as a tool to study tumor-related EMT. In particular,
Py2T cells may serve to corroborate recent findings relating EMT to cancer cell stemness, to therapy resistance and to tumor
recurrence.
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Introduction
Epithelial to mesenchymal transition (EMT) is an embryonic
cellular program during which polarized epithelial cells lose their
cell-cell adhesions and convert into a motile mesenchymal cell type
[1,2]. These phenotypic changes can be induced by a plethora of
signals, including hypoxia, Wnt signaling, epidermal growth factor
(EGF), hepatocyte growth factor (HGF), transforming growth
factor b (TGFb), and many more [3,4]. Intracellular signaling
pathways then integrate these signals to initiate the acquisition of
mesenchymal traits via an elaborate network of EMT-related
transcription factors [5], culminating in the loss of E-cadherin,
a central hallmark of an EMT [6]. In the adult, an analogous
program can be reactivated in the setting of solid tumors (termed
oncogenic or Type III EMT) [7]. During the last two decades,
EMT has been in the focus of many research fields and
laboratories [2]. One long-standing interest is based on the
concept that EMT of cancer cells facilitates their dissociation from
primary tumors and their invasion of surrounding tissue and
intravasation, thereby contributing to the initial steps of metastasis
[1,8,9]. Consistent with the metastatic role of an EMT, recent
results have indicated that EMT confers stem cell-like traits to
tumor cells [10–12]. These results have also provided an attractive
explanation for the findings that an oncogenic EMT contributes to
resistance against cancer therapy, escape from oncogene addiction
and recurrence of tumor growth [13–16]. A number of normal
and transformed cell lines of murine and human origin have been
described and used to study EMT in vitro, yet model systems that
allow the study of breast cancer EMT both in vitro and in vivo have
remained scarce.
To meet this need, we set out to establish a cellular model of
breast cancer EMT that with one cellular system allows the study
of epithelial plasticity in vitro and of EMT and malignant tumor
progression in vivo. We here report the establishment of a cell line
(Py2T) derived from a primary breast tumor of MMTV-PyMT
transgenic mice. Py2T cells undergo EMT in vitro upon TGFb
stimulation and, upon orthotopic injection into syngeneic or nude
mice, they form primary tumors with an EMT-like phenotype,
which is at least in part dependent on the responsiveness of the
transplanted tumor cells to TGFb signaling.
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Results
Py2T, a Novel Breast Cancer Cell Line Undergoing TGFb-
induced EMT
To establish a cellular model system that could be used to study
epithelial to mesenchymal transition (EMT) in vitro and also in vivo,
we sought to establish stable cancer cell lines from primary breast
tumors. Since EMT is regarded as a prerequisite in the early steps
of metastasis, we chose to isolate cells from tumors of the highly
metastatic MMTV-PyMT mouse model of breast cancer [18,19].
After recovery from culture shock and passaging for 2 months, an
isolated pool of cells displayed a uniform cobblestone-like
morphology typical of differentiated epithelial cells (Figure 1A).
We termed this cell line Py2T (Polyoma-middle-T tumor). The
presence of the MMTV-PyMT transgene in these cells could be
confirmed by genotyping (Figure 1B). Curiously, PyMT transgene
expression was not maintained during extended culturing
(Figure 1C).
Next, we investigated whether treatment with a selection of
known inducers of EMT [3] could induce EMT-like morpholog-
ical changes in cultured Py2T cells. Both transforming growth
factor b (TGFb) and hepatocyte growth factor/scatter factor
(HGF) provoked loss of cell-cell contacts, which was not observed
with other treatments, even after prolonged treatment for 10 days
(Figure 1D). Interestingly, only TGFb treatment resulted in
a classical ‘‘cadherin-switch’’, a hallmark of EMT in which
expression of the epithelial cell adhesion molecule E-cadherin is
lost and expression of mesenchymal N-cadherin is gained [29].
Furthermore, we observed an upregulation of the mesenchymal
marker fibronectin only in TGFb-treated cells and to a lesser
extent in EGF-treated cells (Figure 1E). Therefore, among all the
factors tested, only TGFb induced a bona fide EMT in Py2T cells.
TGFb is known to exert cytostatic effects via effector arms
downstream of the canonical Smad2/3 pathway in normal cells.
However, cancer cells often develop resistance to TGFb-induced
cell cycle arrest [30]. The canonical TGFb pathway was activated
in Py2T cells upon TGFb treatment, indicated by the nuclear
translocation of the Smad2/3 complex and the activation of
Smad3 by phosphorylation (Figure S1A). Furthermore, transient
transfection of a promoter reporter construct in which firefly
luciferase expression was under the control of a Smad-binding
element (SBE) revealed a dramatic induction of transcriptional
activity upon TGFb stimulation, while there was no detectable
activity in untreated cells (Figure S1B) [23]. Despite an intact
canonical pathway, we did not observe any significant increase in
cell cycle arrest or apoptosis upon TGFb treatment of Py2T cells
(data not shown).
To establish an experimental system that allowed direct
comparison of epithelial versus mesenchymal cells without prior
lengthy TGFb treatment, Py2T cells were treated with TGFb for
20 days and subsequently maintained as mesenchymal subline
(Py2T LT) in growth medium containing TGFb. Conveniently,
Py2T LT cells preserved their mesenchymal phenotype, even
when frozen and re-cultured in the presence of TGFb. As
confirmed by immunoblotting analysis, Py2T LT cells displayed
a lack of E-cadherin expression, along with high expression of the
mesenchymal markers N-cadherin and fibronectin (Figure 1F).
Furthermore, immunofluorescence staining against E-cadherin
and the mesenchymal marker vimentin were mutually exclusive in
Py2T and Py2T LT cells, respectively, further verifying their
distinct epithelial and mesenchymal states (Figure 1G left).
To determine the cell type represented by Py2T cells and to
further characterize the effects of TGFb-induced EMT on cellular
identity, we stained for relevant breast cancer and mammary
gland cell lineage markers. As the bulk of MMTV-PyMT tumors
consist of luminal, estrogen receptor a (ERa)-positive epithelial
cells, we expected Py2T cells to display a similar expression
pattern. Indeed, we could detect nuclear ERa staining in
untreated cells, indicative of luminal differentiation (Figure 1G
middle). Py2T LT cells however did not stain positive for ERa,
consistent with a role of ERa in maintaining an epithelial
phenotype and suppressing EMT [31]. To determine whether
Py2T cells represent a luminal or a basal mammary gland cell
subtype, we stained for luminal cytokeratin 8/18 (CK8/18) and
for basal cytokeratin 14 (CK14). Interestingly, Py2T cells were
double-positive for these markers, while, consistent with the loss of
the epithelial phenotype, Py2T LT cells only weakly stained for
CK8/18 and lacked CK14 (Figure 1G right, see also Figure 2B).
We also performed gene expression profiling by Affymetrix
DNA oligonucleotide microarray analysis of Py2T and Py2T LT
cells (Table S1). The gene expression profiles were compared to
molecular breast cancer subtypes using the PAM50 predictor
established by Parker and colleagues [20], followed by the 9-cell
line claudin-low predictor [32]. This bioinformatic analysis
revealed that the gene expression profile of Py2T cells resembles
a Her2-enriched breast cancer subtype, whereas the Py2T LT cell
line represents the highly invasive claudin-low subtype (data not
shown).
EMT Kinetics and Plasticity in Py2T Cells
To characterize the transition from an epithelial to a mesenchy-
mal phenotype in a time-resolved fashion, we analyzed various
hallmarks of EMT upon TGFb treatment of Py2T cells over time.
On a morphological level, TGFb treatment led to a gradual loss of
cell-cell contacts and scattering already after 1 day of TGFb
treatment, while cell elongation and filopodia formation gradually
increased over several days (Figure 2A). Immunoblotting analysis
revealed a downregulation of E-cadherin expression over seven
days, whereas N-cadherin levels began to increase between four
and seven days, illustrating a classical cadherin switch (Figure 2B)
[29]. Maximum fibronectin expression was observed already after
one day of TGFb treatment. Expression of the luminal CK8/18
was found reduced yet with significant expression remaining even
after thirteen days of treatment, whereas the expression of basal
CK14 was completely lost after seven days. We further examined
the transcriptional regulation of well-known EMT markers by
quantitative RT-PCR (Figure 2C). The kinetics of mRNA levels of
E-cadherin, N-cadherin and fibronectin closely correlated with the
immunoblotting analysis (Figure 2B and C). Furthermore, we
observed a strong and gradual increase in mRNA levels of
vimentin and the E-cadherin gene repressors Zeb1 and Zeb2,
a robust early induction of Snail mRNA, and only a modest
increase in mRNA levels of the other E-cadherin repressors Slug,
E47 and Twist (Figure 2C). Overall, these time-course experi-
ments demonstrated that in Py2T cells TGFb-induced EMT
involved gradual changes in gene expression, with early events
occurring already after one day (loss of cell-cell contact,
upregulation of fibronectin and Snail), while others were observed
at later stages of EMT (cadherin switch, expression of vimentin,
Zeb1 and Zeb2).
After having studied the transition from an epithelial to
a mesenchymal state, we wondered whether Py2T cells that had
undergone EMT could also revert back to the epithelial state and
undergo a mesenchymal to epithelial transition (MET) upon
withdrawal of TGFb. We observed that Py2T cells cultured for up
to 30 days in growth medium containing TGFb were still able to
revert to the original epithelial morphology when TGFb was
withdrawn from the medium. The MET process took approxi-
Py2T EMT Model
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Figure 1. Establishment of a murine breast cancer cell line undergoing TGFb-induced EMT. (A) Primary tumor cells were isolated from an
advanced breast tumor of a MMTV-PyMT transgenic female mouse and were cultured for at least 2 months prior to further experimentation, resulting
in a novel cell line termed Py2T. (B) Py2T cells maintain the MMTV-PyMT transgene. The MMTV-PyMT transgene was detected by PCR and agarose gel
electrophoresis. DNA from an MMTV-PyMT tumor and from normal murine mammary gland (NMuMG) cells served as positive and negative controls,
respectively. (C) Py2T cells lost the expression of the MMTV-PyMT transgene. Immunoblotting for the PyMT protein was performed on lysates of Py2T
cells untreated or treated with 0.1 mM Dexamethasone for up to 72 h to induce the MMTV promoter. Lysates of an MMTV-PyMT tumor and NMuMG
cells served as positive and negative controls, respectively. (D) Treatment of Py2T cells with known EMT inducers. Cells were continuously treated
with the indicated growth factors and cytokines for 10 days (2 ng/mL TGFb1; 50 ng/mL EGF; 10 ng/mL IGF-I; 50 ng/mL HGF; 20 ng/mL FGF-2; 20 ng/
mL PDGF-BB; 50 ng/mL IL-6). Potential morphological changes were analyzed by phase-contrast microscopy. (E) Expression of epithelial (E-cadherin)
Py2T EMT Model
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mately 18 days (Figure 2D), with a gradual re-establishment of E-
cadherin expression during this time (Figure 2E). These results
indicate that Py2T cells offer a valuable experimental system to
study the multiple stages of EMT and its reversion, MET.
Non-canonical TGFb Signaling is Responsible for Early
Morphological Changes
To obtain a more detailed picture of the mechanisms leading to
the striking morphological alterations after the first day of EMT
induction, we investigated the contribution of canonical and non-
canonical TGFb signaling to these processes. We first ablated
Smad4 expression to block canonical TGFb signaling [33]. We
could not observe a block of morphological alterations or junction
dissolution in cells depleted of Smad4 after one day of TGFb
treatment, indicating that canonical TGFb signaling is not
required for the initial changes in cell morphology (Figure 3A–B).
Non-canonical signaling by TGFb involves the activation of p38
and Jnk MAP kinases via activation of Tak1 by receptor-associated
TRAF6 and of Erk1/2 MAP kinase by recruitment and
phosphorylation of Shc by TGFbRI and subsequent activation
of MEK1/2 [34]. These mediators have been well established to
contribute to TGFb-induced EMT [35–40]. Indeed, inhibition of
these pathways by chemical inhibitors was sufficient to at least
partially block the pronounced morphological changes observed
after one day of TGFb treatment (Figure 3C). In addition, other
non-canonical TGFb-induced signals are known to contribute to
EMT, such as RhoA degradation at cell junctions, which results in
junction disassembly [41]. We indeed observed a slight decrease in
total RhoA expression levels after one day of TGFb treatment
(Figure 3D). We experimentally mimicked TGFb-induced down-
regulation of RhoA by siRNA-mediated knockdown in epithelial
Py2T cells, which resulted in a partial disruption of tight and
adherens junction (Figure 3E–F).
Together, these results illustrate that short-term TGFb treat-
ment of Py2T cells evokes cell-cell junction disassembly and
pronounced phenotypic changes mainly by non-canonical TGFb
signaling.
Migratory and Invasive Properties upon EMT Induction
To evaluate whether Py2T cells could be a suitable in vitro
model system to study functional consequences of EMT, we
assessed the migratory and invasive capabilities of these cells
before, during and after EMT. First, we employed a modified
Boyden chamber assay to analyze whether and to what extent
Py2T cells become migratory and invasive during EMT. Cells
previously treated with TGFb for different times were seeded into
Boyden chamber inserts without (migration assay) or with Matrigel
coating (invasion assay) and were allowed to move towards
a gradient of fetal bovine serum (FBS). Quantification of cells that
traversed the membrane revealed that cells treated with TGFb for
seven or more days were more migratory compared to untreated
cells, and the migratory capacity dramatically increased with
longer TGFb treatment (Figure 4A top left). Similarly, when seeded
into Boyden chambers pre-coated with Matrigel, the cells passed
through the bottom of the chambers with a similar increase over
the time of TGFb treatment (Figure 4A top right). To illustrate these
results, we stained cells located on the bottom side of the insert
membranes with crystal violet (Figure 4A bottom). These findings
clearly demonstrate that Py2T cells display a dramatic increase in
chemotactic, single cell migration and invasion upon induction of
EMT.
Scratch wound closure is another frequently used assay to assess
the migratory capacity of cells on tissue culture plastic. Untreated
and TGFb-treated Py2T cells were grown to confluence and then
starved in serum-free medium. After scratching a gap into
confluent monolayers, we followed gap closure by live cell imaging
(Movies S1 and S2). Figure 4B shows images at different time
points after wounding. Interestingly, untreated Py2T cells closed
the scratch wound already after 12 hours in a sheet-like fashion,
demonstrating that they are capable of a collective mode of
migration, indicative of a metastable state [42]. Py2T cells treated
with TGFb closed the scratch wound much slower, moving in
a mesenchymal mode of single cell migration and displaying front-
rear polarity. These observations indicate that TGFb treatment
switches Py2T cells from a collective to a single cell migration
mode [43].
To compare the migratory and invasive capabilities of Py2T
and Py2T LT cells in a more physiological setting, the cells were
seeded into a three-dimensional extracellular matrix (Matrigel;
Figure 4C). Cells cultured on plastic are shown for comparison
(Figure 4C, left; see also Movies S3 and S4 for live imaging). When
cultured for 6 days in growth factor-reduced Matrigel, Py2T cells
formed spheres. In contrast, Py2T LT cells invaded the
surrounding matrix (Figure 4C middle). To further examine these
different phenotypes, we performed in-gel immunofluorescence
staining of intact three-dimensional structures, followed by
confocal microscopy. Double-staining of Py2T spheres with
antibodies against E-cadherin and ZO-1 revealed densely packed
cells with intact adherens and tight junctions, respectively
(Figure 4C top right). In contrast, Py2T LT structures, stained
against vimentin and fibronectin, invaded the matrix as single cells
or as cell trails (Figure 4C bottom right). The phenotypic differences
between Py2T and Py2T LT cells grown in extracellular matrix
became even more apparent upon reconstructing the confocal
microscopy stacks to three-dimensional models using Imaris
software (Figure 4D, see also Movies S5 and S6 for animation).
This analysis revealed the invasion and indian-file-like trailing of
Py2T LT cells as single cells. Interestingly, only the leading cells
expressed vimentin, while all Py2T LT cells cultured on a two-
dimensional surface were positive for vimentin (Figure 1G) and
moved as single cells rather than being organized in trails (Movie
S6). Taken together, these data demonstrate that the Py2T cell line
represents a valuable model system to study various aspects of cell
migration and invasion in the context of EMT.
Invasive Tumor Formation upon Orthotopic
Transplantation into Syngeneic Mice
We next orthotopically transplanted Py2T cells into mammary
fat pads of mice to evaluate their tumorigenicity. Since Py2T cells
have been derived from tumors of MMTV-PyMT mice in an
FVB/N background and because the PyMT transgene was no
more expressed in cultured cells, we transplanted Py2T cells into
syngeneic FVB/N mice. Three mice were injected with
16106 cells, all of which developed tumors. After 27 days of
and mesenchymal (N-cadherin, fibronectin) markers were analyzed by immunoblotting of the lysates of cells treated in (D). (F) Immunoblotting
analysis of EMT marker expression in Py2T and Py2T LT cells. The mesenchymal subline Py2T LT (long-term) was generated by TGFb-treatment of Py2T
cells for at least 20 days, and was subsequently maintained in TGFb containing growth medium. (G) Analysis of markers for EMT and breast cell type
before and after TGFb-induced EMT. Immunofluorescence staining was performed with antibodies against E-Cadherin (epithelial marker), vimentin
(mesenchymal marker), estrogen receptor alpha (ERa), cytokeratin 8/18 (luminal markers) and cytokeratin 14 (basal marker). Scale bar, 20 mm.
doi:10.1371/journal.pone.0048651.g001
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growth, tumors were harvested and analyzed. Haematoxylin &
Eosin (H&E) staining of histological sections of a Py2T tumor
(Figure 5A, right) and a late stage MMTV-PyMT tumor (Figure 5A,
left) revealed that MMTV-PyMT tumors were mainly well
differentiated with some less well-differentiated areas and necrosis
towards the tumor center. The tumor borders were passively
Figure 2. Kinetics and reversibility of TGFb-induced EMT in Py2T cells. (A) Morphological changes of Py2T cells during a time-course of
TGFb-treatment. Cells were cultured in growth medium containing TGFb (2 ng/ml) and phase-contrast microscopy pictures were taken at the
indicated times. (B) Immunoblotting analysis of lysates prepared from Py2T cells treated as in (A). The expression of epithelial (E-cadherin),
mesenchymal (N-cadherin, fibronectin), luminal (CK8/18) and basal (CK14) markers was analyzed. (C) Changes in the expression of EMT markers
during TGFb-induced EMT of Py2T cells. Py2T cells were treated for 10 days with TGFb as described in (A). RNA was extracted at the indicated time
points of TGFb-treatment and quantitative RT-PCR was performed with primers specific for the EMT markers indicated. Expression levels are shown as
mean fold difference of untreated cells (0d) 6 S.E.M of 5 independent experiments. (D–E) Reversibility of TGFb-induced EMT. Py2T cells were treated
with TGFb for 30 days to induce EMT and were then further cultured without TGFb for additional 30 days. Phase-contrast microscopy images were
taken at the indicated time points (E). E-cadherin expression levels were analyzed throughout the experiment by immunoblotting (F).
doi:10.1371/journal.pone.0048651.g002
Py2T EMT Model
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invading the fat pad by proliferation (pushing borders). In contrast,
Py2T tumors were characterized by streams of elongated cells that
were actively invading the surrounding fat tissue. Of note, Py2T
tumors lacked excessive necrosis, possibly because they were well
vascularized as determined by staining for the blood vessel marker
CD31 (data not shown). Furthermore, Py2T tumors contained
a high stromal component intermixed with tumor cells. To
exclude the possibility that immune cell infiltration was due to
a possible re-expression of the PyMT transgene, tumor tissue
sections were stained with an antibody against the PyMT protein.
As expected, PyMT expression could be detected in MMTV-
PyMT tumors (Figure 5B, left), but not in Py2T tumors (Figure 5B,
right). When Py2T cells were orthotopically implanted into
immuno-deficient nude mice, all mice developed tumors with
a substantial infiltration of CD45-positive stromal cells, with a high
content of macrophages (Figure S2).
The spindle-like appearance of cells in the Py2T tumors
suggested that Py2T cells might have undergone an EMT in these
tumors. We thus compared lysates from mainly epithelial MMTV-
PyMT tumors with lysates from mainly invasive Py2T tumors for
expression of EMT markers. Indeed, expression of E-cadherin in
MMTV-PyMT tumors was readily detectable as expected,
however, very little if any E-cadherin expression was detectable
in lysates of Py2T tumors (Figure 5C), supporting the hypothesis
that Py2T cells had undergone EMT-like changes in vivo.
Expression of the mesenchymal markers fibronectin and N-
cadherin was also higher in some but not all Py2T tumors as
compared to MMTV-PyMT tumors. Collectively, these results
demonstrate that Py2T cells are tumorigenic, despite the absence
of PyMT expression, and that they undergo oncogenic EMT-like
changes in vivo. Notably, neither FVB/N nor immuno-deficient
mice bearing Py2T tumors developed apparent metastasis, as
determined by histological sectioning of various organs (data not
shown).
TGFb-dependent EMT of Py2T Tumors
We next assessed whether the EMT occurring during Py2T
tumor growth in the mammary fat pad of mice could be attributed
to stimulation by host-derived TGFb. First, we generated Py2T
cell lines that stably express GFP for their distinction from host
stromal cells. Next, we superinfected these cells with a lentiviral
construct encoding a dominant-negative form of TGFb receptor II
(TBRDN) [26] or empty vector as control. Cultured Py2T
TBRDN-expressing cells did not show any apparent changes in
phenotype as compared to control cells in the absence of TGFb,
but were resistant against TGFb-induced EMT (Figure S3A). In
a next step, we transplanted Py2T control and Py2T TBRDN into
fat pads of immuno-deficient nude mice to evaluate their ability to
undergo EMT in vivo. All mice developed tumors, and tumor
growth was not significantly different between the two experi-
mental groups, although TBRDN tumors tended to grow more
slowly with increasing size in comparison to Py2T control tumors
(Figure S3B). H&E staining of Py2T control tumors revealed the
same stream-like cellular growth pattern as observed in Py2T
tumors in FVB/N mice (Figure 6A top left), with cells displaying
a spindle-like morphology (Figure 6A bottom left). Interestingly,
tumors formed by Py2T TBRDN contained patches of more
differentiated appearance (Figure 6A top right), with cells adopting
a round, differentiated morphology (Figure 6A bottom right).
However, Py2T TBRDN tumors also contained a significant
portion of mesenchymal areas (Figure 6A right), suggesting that in
these areas, Py2T cells underwent EMT in response to signals
other than TGFb.
Analysis of the expression of EMT markers revealed that, Py2T
control tumors were negative for E-cadherin expression (Figure 6B,
top left), whereas the more differentiated regions in TBRDN tumors
strongly expressed E-cadherin (Figure 6B, top right). These results
indicated that the inhibition of TGFb signaling in Py2T TBRDN
cells was sufficient to prevent a loss of E-cadherin expression and
to preserve an epithelial phenotype in some but not all tumor
areas. Immunofluorescence microscopy analysis of E-cadherin
staining of GFP-expressing Py2T and Py2T TBRDN tumor cells,
respectively, confirmed these observations (Figure 6C). Further-
more, immunoblotting analysis demonstrated higher E-cadherin
expression in Py2T TBRDN tumors in contrast to Py2T control
tumors (Figure 6D). Py2T tumors also contained a large amount of
cells that stained positive for the mesenchymal marker vimentin,
however, these vimentin expressing cells represented stromal cells
rather than Py2T cells, as revealed by a lack of GFP expression
(Figure 6E). Hence, although capable of vimentin upregulation
upon EMT induction in vitro (Figure 2C), Py2T cells failed to
upregulate vimentin in vivo, suggesting that EMT in transplanted
tumors is incomplete, which is often reported as a hallmark of
oncogenic EMT [44]; (see also Discussion).
As Py2T cells expressed both luminal (CK8/18) and basal
(CK14) markers in culture (Figure 1G, Figure 2B), we were curious
to see whether the EMT-like changes observed in tumors would be
accompanied by changes in the expression of these cell lineage
markers. Immunohistochemistry staining (Figure 6B) and immu-
noblotting analysis (Figure 6D) revealed a switch-like change in
expression: a loss of CK14 expression was observed in favor of
CK8/18 expression in Py2T tumors. On the other hand, the
epithelial patches of Py2T TBRDN tumors were strongly positive
for CK14 expression and displayed a reduction or even a loss of
CK8/18 expression. Together, these results demonstrate that
Py2T tumors display EMT-like changes characterized by a loss of
E-cadherin expression, and suggest an apparent differentiation
along the luminal lineage, both of which is inhibited in distinct
tumor areas by blocking the TGFb responsiveness of the tumor
cells.
Figure 3. Early morphological changes and junction disassembly can be attributed to non-canonical TGFb signaling pathways. (A)
Smad-mediated canonical TGFb signaling is dispensable for early changes in morphology and junction disruption. Cells were transfected with a pool
of siRNAs against Smad4 or a non-targeting pool and were then treated or not with TGFb for 1 day as indicated. Fixed cells were stained for the
adherens junction components E-cadherin and b-catenin, or for E-cadherin and the tight junction component ZO-1. Note the relocalization of b-
catenin from adherens junctions to the cytoplasm upon TGFb-treatment. Scale bars, 50 mm. (B) Immunoblot analysis of lysates from the experiment
described in (A) to control for Smad4 knockdown efficiency. (C) Requirement of non-canonical TGFb signaling pathways on early morphological
changes and junction disassembly. Cells were pre-treated for 4 hours with chemical inhibitors of the kinases indicated, and were then treated with
TGFb for 1 day and analyzed as described in (A). Scale bars, 50 mm. (D) RhoA expression levels during the early stages of EMT. Cells were treated or
not with TGFb for 1 day and RhoA expression levels were analysed by immunoblotting. (E) Importance of RhoA levels for tight- and adherens junction
integrity. Epithelial Py2T cells were separately transfected with two different siRNAs targeting RhoA to achieve expression levels comparable to those
observed in Py2T cells treated with TGFb (see D). Cells were stained for the adherens junction components E-cadherin and b-catenin, or for E-cadherin
and the tight junction component ZO-1. (F) Immunoblotting analysis to determine the RhoA knockdown efficiency in the experiment described in (E).
doi:10.1371/journal.pone.0048651.g003
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Discussion
We herein report the generation and characterization of a stable
murine breast cancer cell line, named Py2T, from a primary breast
tumor of an MMTV-PyMT transgenic mouse. Cultured Py2T
cells can be induced to undergo a full EMT by TGFb treatment,
a multistage process that takes up to ten days and results in
a complete loss of epithelial morphology and epithelial marker
expression, and the gain of mesenchymal marker expression and
increased cell migration and invasion. Upon long-term treatment
with TGFb, Py2T cells maintain the mesenchymal differentiation
status (Py2T LT), allowing the direct comparison between the
extreme stages of epithelial-mesenchymal plasticity. Upon removal
of TGFb, Py2T LT cells revert to their epithelial origin by
undergoing an MET, with the gain of epithelial morphology and
marker expression. Our pharmacological interference studies
reveal that the early stages of TGFb-induced EMT in Py2T cells
depend on non-canonical TGFb signaling, involving Jnk, p38 and
ERK1/2 MAP kinase signaling and the degradation of the small
GTPase RhoA. In contrast, Smad4 and with it canonical TGFb
signaling appears to be dispensable for this process.
Py2T cells also offer a novel syngeneic orthotopic trans-
plantation model of malignant breast cancer progression. Upon
injection into the fat pads of syngeneic FVB/N mice or into
Figure 4. Changes of migratory and invasive properties of Py2T cells before, during and after TGFb-induced EMT. (A) Boyden
chamber migration and invasion assay. Cells were treated with TGFb for the indicated times (LT = long term treatment, as described in Fig. 1F). 25’000
cells were seeded into migration or invasion chambers in duplicate in the absence or presence of TGFb and allowed to pass through the membrane
pores for 24 hours along an FBS gradient. Invasion chambers were pre-coated with growth-factor reduced Matrigel (BD BioCoat chambers). Cells that
passed through the membrane pores were stained with crystal violet and photographed (bottom panels) and then counted (top graphs). Results are
expressed as mean6 S.E.M of three independent experiments. (B) Scratch wound healing assay. Cells pre-treated with TGFb or not as indicated were
starved over night and scratch wounds were introduced into confluent monolayers. Scratch wound closure was monitored by an IncuCyteTM live cell
imaging system. Black masking represents initial gap width at 0 hours. Note the collective, sheet-like wound closure by untreated Py2T cells in
contrast to single cell wound infiltration of TGFb-treated cells (also see Movies S1 and S2 for live imaging data of this experiment). (C) Morphology of
epithelial Py2T cells and mesenchymal Py2T LT cells grown on plastic tissue culture dishes (2D) and in Matrigel (4 mg/ml; 3D). Structures were grown
for 6 days, and stained directly in Matrigel with antibodies against epithelial E-cadherin and ZO-1 or against mesenchymal vimentin and fibronectin.
Immunofluorescence images were acquired by confocal microscopy. Scale bars, 25 mm. (D) Three-dimensional reconstruction of confocal imaging
stacks from cells grown in Matrigel as described in (A) (See also Movies S5 and S6 for rotating 3D models). Scale bars, 25 mm.
doi:10.1371/journal.pone.0048651.g004
Figure 5. Orthotopic transplantation of Py2T cells into syngeneic mice results in the formation of invasive tumors. (A) H&E staining of
histological sections from tumors of MMTV-PyMT transgenic mice and from transplanted Py2T tumors. 16106 Py2T cells were transplanted into the
fat pad of 8 weeks old female FVB/N mice and allowed to grow tumors for 27 days. Late-stage MMTV-PyMT tumors were from 12 weeks old female
mice. Bottom panels: enlarged regions indicated by the white squares in the top panels. Note the typical pushing borders in MMTV-PyMT tumors in
contrast to stream-like invasion of fat tissue in Py2T tumors. Scale bars, 200 mm. (B) Polyoma-middle-T (PyMT) expression in MMTV-PyMT and Py2T
tumors. Paraffin sections were stained with an antibody against PyMT. Immunohistochemical staining in the absence of primary antibody (1u) was
used as negative control. Scale bar, 100 mm. (C) Immunoblotting analysis for EMT markers in tumor lysates of MMTV-PyMT and Py2T tumors. Lysate
from cultured Py2T cells is included as a control. Note the loss of E-cadherin expression and upregulation of mesenchymal markers (N-cadherin,
fibronectin) in Py2T tumors.
doi:10.1371/journal.pone.0048651.g005
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immuno-deficient nude mice, Py2T cells form primary tumors and
spontaneously undergo EMT-like changes in vivo. As a proof of
concept for the dual in vitro and in vivo use of Py2T cells as models
of murine breast cancer cells undergoing EMT, we blocked TGFb
responsiveness of Py2T cells by stable expression of a dominant-
negative version of TGFbRII. Transplantation of these cells
yielded tumors containing areas with an epithelial phenotype,
showing that the EMT-like changes in Py2T cell-derived tumors
are, at least in part, dependent on TGFb stimulation. These
experiments approve Py2T cells as a versatile model for functional
studies of murine breast cancer cells undergoing EMT in vitro and
in vivo.
It has been recognized that breast cancer is not a single, but
a heterogenous disease of various subtypes, which can be
categorized according to staining for marker combinations, or,
more recently, by molecular subtyping according to gene
expression profiles. The type of breast cancer is largely dictated
by the transforming oncogene and the cell of origin being
transformed [45–48]. We therefore characterized the cell type
represented by Py2T cells. Molecular subtyping of MMTV-PyMT
tumors has previously shown that these tumors resemble the
luminal subtype of human breast cancer [45,49], as would be
expected from the fact that the MMTV promoter is active in
luminal epithelial cells [50,51]. Consistent with their origin from
a tumor of an MMTV-PyMT transgenic mouse, Py2T cells are
positive for the luminal markers estrogen receptor (ER) and CK8/
18 (Figure 1G). Interestingly, Py2T cells also co-express the basal
marker CK14 (Figure 1G) and therefore do not display a purely
luminal phenotype. Concomitant basal and luminal cytokeratin
expression has also been observed in a luminal breast cancer
model where the MMTV promoter has been used to drive mutant
PIK3CA H1047R oncogene expression [52], and one of the
pathways activated by PyMT is the PI3K pathway [53], suggesting
that similar mechanisms are involved. Our observations and those
of others show that MMTV-PyMT tumors also contain a fraction
of CK14-positive tumor cells (data not shown) [54]. Furthermore,
simultaneous expression of CK8/18 and CK14 has been
established as a hallmark of basal cell lines [55].
Together, these considerations suggest that Py2T cells should be
categorized as a basal cell line with luminal origin. It is interesting
to note in this context that EMT-like changes have most
commonly been observed in the basal-like subgroup of breast
cancers, indicating that this subgroup is predisposed for EMT-like
changes [56,57]. Basal-like tumors also encompass the recently
determined claudin-low subtype, now considered to be a distinct
entity, which is clearly enriched in EMT marker expression
[21,58,59]. Our gene expression profiling and subsequent
bioinformatic analysis according to the PAM50 and 9-cell line
claudin-low predictor [20,32] revealed that Py2T cells most closely
resemble Her2-enriched breast cancer of patients. In contrast,
Py2T cells that have undergone TGFb-induced EMT (Py2T LT)
resemble basal-like, claudin-low breast cancer, a highly invasive
breast cancer subtype that has been shown to correlate with EMT
in a variety of experimental systems [32,58,60,61].
Expression of basal cytokeratins 5 and 14 has also been linked to
a hybrid or metastable differentiation state, in which cells display
considerably more plasticity than fully differentiated cells, residing
in a dynamic continuum between epithelial and mesenchymal
states [42,44]. One feature that characterizes metastable cells is
that they display loose but intact cell-cell adhesions and show
migratory properties in the form of collective movement as a sheet.
Indeed, when grown to confluence, Py2T cells close a scratch
wound as a cellular sheet (Figure 4B and Movie S1). A further
indicator for a metastable state is the observation that, when
grown under sparse culture conditions on plastic, Py2T cells are
able to transiently leave the epithelial sheet and move as single
cells in a spontaneous manner (Movie S3). This single cell mode of
migration resembles amoeboid movement, characterized by
a rounding of cell bodies and a fast change in direction, and is
distinct from the mesenchymal mode of migration characterized
by front-rear polarity which we observed with Py2T LT cells
(Movie S4) [43,62]. The reversibility of TGFb-induced EMT of
Py2T cells further illustrates the plasticity of Py2T cells and has
also been proposed as a hallmark of metastability (Figure 2E)
[42,44,63]. From these observations we conclude that cultured
Py2T cells do not represent fully differentiated epithelial cells, but
that they are rather in a metastable state that is readily shifted
towards a mesenchymal phenotype by TGFb treatment.
When implanted into the mammary fat pad microenvironment,
Py2T cells eventually develop tumors with an EMT-like pheno-
type (Figures 5 and 6). We believe that the term ’’EMT-like‘‘ is
accurate, since we have noticed that in these tumors, Py2T cells do
not completely convert into mesenchymal cells as they do under
culture conditions in the presence of TGFb. Breast cancers can
display a range of stages of EMT, in fact, tumor-associated EMT
appears less complete than developmental EMT [7,64]. A staging
scheme has been proposed based on the state of cell polarization,
cell cohesiveness and intermediate filament expression, categoriz-
ing oncogenic EMT into four distinct stages (P0–P3), with P0
designating full epithelial differentiation and P3 indicating a fully
mesenchymal state [44]. Py2T tumors correspond to the P2 stage,
where cells have lost polarization and cohesive cell-cell contacts,
but retain cytokeratin expression (at least CK8/18) and fail to
upregulate vimentin (Figure 6). When we block TGFb-respon-
siveness in Py2T cells, epithelial morphology is retained in distinct
areas, where tumor cells appear to be organized as dynamic
cohesive sheets or strand-like structures, however not regaining full
epithelial polarization (Figure 6). This phenotype is again
consistent with a metastable state rather than full epithelial
differentiation, and corresponds to the P1 stage of oncogenic EMT
according to [44].
Despite the fact that Py2T cells form locally invasive tumors and
that MMTV-PyMT tumors give rise to distant metastases, we
were unable to detect any apparent metastases evoked by Py2T
tumors. One conceivable reason for this apparent discrepancy
Figure 6. Tumors of TGFb-resistant Py2T cells contain areas with a more epithelial phenotype. (A) Morphology of tumors generated from
Py2T cells stably overexpressing a dominant-negative TGFbRII (Py2T TBRDN) or empty vector control cells (Py2T). 16106 cells were injected into fat
pads of nude mice and tumors were grown for 24 days. Paraffin sections were stained with H&E. Note the appearance of more differentiated
epithelial areas in Py2T TBRDN tumors. Top: Epithelial (E) and mesenchymal (M) regions are separated by the dashed line (Scale bar, 200 mm). Bottom
panels show larger magnification (Scale bar, 50 mm). (B) Expression of EMT and lineage markers in Py2T tumors and in the more epithelial areas of
Py2T TBRDN tumors. Immunohistochemical staining of paraffin sections was performed using the specified antibodies. White squares show higher
magnification. Scale bar, 100 mm. (C) Immunofluorescence staining of frozen sections of GFP-labeled Py2T and Py2T TBRDN tumors as described in
(A) with antibodies against E-cadherin (red) and Py2T tumor cells (green). Scale bar, 20 mm. (D) Immunoblotting analysis of epithelial and cytokeratin
lineage markers in a series of Py2T and Py2T TBRDN tumors as indicated. (E) Immunofluorescence staining of frozen sections of GFP-labeled Py2T and
Py2T TBRDN tumors as described in (A) with antibodies against vimentin (red) and Py2T tumor cells (green). Scale bar, 20 mm.
doi:10.1371/journal.pone.0048651.g006
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could be the following: Py2T tumors appeared fast growing and
aggressive and, due to animal welfare considerations, mice had to
be sacrificed approximately 25 days after implantation (Figure
S3B). Therefore, the timeframe to establish detectable metastasis
may be simply too short. In comparison, the metastasis latency in
MMTV-PyMT tumors is about 3.5 months [65].
We have observed that PyMT transgene expression is absent in
Py2T cells both in vitro (Figure 1C) and in vivo (Figure 5B). This
finding has important implications. First, it allows the trans-
plantation of Py2T cells (derived from MMTV-PyMT mice in
a FVB/N background) into syngeneic FVB/N mice (Figure 5).
Second, the loss of PyMT expression together with the fact that
these cells are nevertheless tumorigenic suggests that outgrowing
Py2T cells that have undergone EMT have escaped oncogene
addiction. In support of this hypothesis, we observed that
mesenchymal Py2T LT cells formed significantly more colonies
when grown under anchorage-independent conditions in soft agar
(Figure S4). Intriguingly, in several other mouse models of breast
cancer, discontinued oncogene expression is followed by the
appearance of tumors that display EMT-like features (see
reference [66] for review). For example, after turning off Her2/
neu expression in tumors induced by this oncogene in the
mammary gland, tumors regress, yet regrow as spindle cell
’’EMT‘‘ tumors that are strikingly similar if not identical in
phenotype to the tumors we describe here [67]. In agreement with
our study, these tumors have not been observed to metastasize
[66]. It is likely that our model recapitulates these events, whose
underlying mechanisms have yet to be determined. If so, the Py2T
model system could be instrumental in elucidating mechanisms of
tumor recurrence and of therapy resistance development, which
has been previously attributed to EMT [13,15,64,68,69]. Finally,
in light of the recent findings that EMT confers stem cell-like traits
to cancer cells [10,11], Py2T cells also offer a unique system to
study these events in vitro and in vivo.
Conclusions
We have established and functionally characterized a novel
cellular model of murine breast cancer EMT (Py2T). While Py2T
cells undergo EMT in response to TGFb stimulation in vitro,
orthotopic transplantation into mice results in tumors displaying
oncogenic, TGFb-dependent EMT. Py2T cells thus represent
a versatile model to investigate the molecular mechanisms
underlying EMT and to delineate how EMT contributes to
therapy resistance, loss of oncogene addiction and tumor re-
currence.
Materials and Methods
Antibodies and Reagents
Antibodies: PyMT (mouse monoclonal Pab762, a kind gift of
Dr. S. Dilworth, Imperial College London), Actin (sc-1616,
SantaCruz Biotechnology), E-cadherin (610182, Transduction
Laboratories, used for immunoblotting and IHC), E-cadherin
(13-1900, Zymed, used for immunofluorescence stainings), N-
cadherin (M142, Takara Bio), fibronectin (F3648 Sigma-Aldrich),
GAPDH (ab9485, Abcam), cytokeratin 14 (RB-9020-P0, Neo-
Markers), cytokeratin 8/18 (20R-CP004, Fitzgerald), vimentin
(V2258, Sigma-Aldrich), ERa (sc-542, Santa Cruz Biotechnology),
ZO-1 (617300, Zymed), F4/80 (MCAP497, Serotec), CD45
(550539, BD), Smad2/3 (610842, BD), Smad3 pSer423/425
(9520, Cell Signalling), b-catenin (C2206, Sigma-Aldrich), Smad4
(sc-7966, Santa Cruz Biotechnology), RhoA (sc-418, Santa Cruz
Biotechnology).
Reagents: recombinant human (rh) TGFb1 (240-B-010, R&D
Systems), recombinant mouse (rm) EGF (PMG8041, Invitrogen),
rmIGF-1 (250-19, Peprotech), rmHGF (2207-HG, R&D Systems),
rmbasicFGF (3139-FB-025, R&D Systems), rhPDGF-BB (220-BB,
R&D Systems, rhIL-6 (200-06 Peprotech), Dexamethasone (800-
437-7500, Chemicon), Matrigel, growth factor reduced (356230,
BD), SB431542 (S4317, Sigma Aldrich), SB203580 (ALX-270-
339, Axxora), SP600125 (ALX-270-339, Axxora), PD98059
(ALX-385-023, Axxora).
Cells and Cell Lines
A subclone of NMuMG cells (NMuMG/E9; hereafter
NMuMG) was a kind gift of Dr. M. J. Wheelock and has been
previously described [17]. NMuMG cells were originally obtained
from the American Type Culture Collection (ATCC, Manassas,
VA). Py2T cells were isolated from a breast tumor of an MMTV-
PyMT female mouse with an FVB/N background. Isolation of this
cell line was done with approval, and according to the rules and
guidelines of, the Swiss Federal Veterinary Office (SFVO) and the
local ethics committee (Cantonal Veterinary Office, Basel-Stadt,
Switzerland); (see also Ethics Statement at the end of this section).
NMuMG and Py2T cells were cultured in DMEM supplemented
with glutamine, penicillin, streptomycin, and 10% FBS (Sigma).
Mouse Strains
MMTV-PyMT [18,19] were received from N. Hynes (FMI,
Basel, Switzerland). BALB/c nude mice were purchased from
JANVIER SAS (Le Genest Saint Isle, France).
Primers
Primers used for quantitative RT-PCR are listed in Table S2.
For genotyping of the MMTV-PyMT transgene, the following
primers were used: MMTV-PyMT (forward: 59-cggcggagcgag-
gaactgagg-39, reverse: 59-tcagaagactcggcagtcttag-39).
Genotyping
To extract DNA, cells from a confluent 10 cm dish were
trypsinized, washed in PBS and pelleted. To the pellet, 450 mL tail
tip buffer (50 mM Tris-HCl pH 8, 100 mM NaCl, 100 mM
EDTA, 1% SDS) and 180 mL 6 M NaCl were added, the samples
were mixed and spun at full speed in a tabletop centrifuge.
Supernatant was added to 600 mL isopropanol, vortexed and spun
for 5 min at full speed. Supernatant was discarded and 500 mL of
70% EtOH was added, vortexed and spun for 3 min at full speed.
Supernatant was discarded and the pellet was dried and
resuspended in TE buffer. Samples were analyzed using standard
PCR procedure.
Quantitative RT-PCR
Total RNA was prepared using Tri Reagent (Sigma-Aldrich),
reverse transcribed with M-MLV reverse transcriptase (Promega,
Wallisellen, Switzerland), and transcripts were quantified by PCR
using SYBR-green PCR MasterMix (Applied Biosystems, Rotk-
reuz, Switzerland). Riboprotein L19 primers were used for
normalization. PCR assays were performed in triplicates, and
fold induction was calculated using the comparative Ct method
(DDCt).
Microarray Gene Expression Profiling and Expression
Analysis
RNA was isolated from Py2T and Py2T LT cells using QIAzol
(Quiagen). RNA quality and quantity was evaluated using an
Agilent 2100 Bioanalyzer (Agilent Technologies). The manufac-
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turer’s protocols for the GeneChip platform by Affymetrix were
followed. Methods included synthesis of the first- and second-
strand cDNA followed by synthesis of cRNA by in vitro
transcription, subsequent synthesis of single-stranded cDNA,
biotin labeling and fragmentation of cDNA and hybridization
with the microarray slide (GeneChipH Mouse Gene 1.0 ST array),
posthybridization washings and detection of the hybridized
cDNAs using a streptavidin-coupled fluorescent dye. Hybridized
Affymetrix GeneChips were scanned using an Affymetrix
GeneChip 3000 scanner. Image generation and feature extraction
were performed using Affymetrix GCOS Software and quality
control was performed using Affymetrix Expression Console
Software. All microarray raw data has been uploaded to the
ArrayExpress Database (Accession number E-MEXP-3731 and is
publicly available (www.ebi.ac.uk/arrayexpress/).
Microarray data was analysed using R statistical programming
(R2.13.0; www.r-project.org) and its Bioconductor packages
(http://www.bioconductor.org). Gene expression was calculated
after RMA normalization and linear modeling using the limma
package. The probesets were annotated to mouse Refseq IDs with
the brainarray annotation package (http://brainarray.mbni.med.
umich.edu) and human homologues were mapped using biomart
(http://www.biomart.org/). Differentially expressed genes were
determined with Empirical Bayes Statistics according to the
following criteria: expression change between Py2T and Py2T LT
of at least 2 fold, an average log expression of at least 3 and
logOdds of at least 0.
Molecular Subtyping
First, intrinsic subtype classification into Luminal A, Luminal B,
Basal-like, HER2-enriched and Normal-like groups was per-
formed using the 50 gene (PAM50) predictor, comparing Py2T
and Py2T LT to the UNC337 training set provided by Parker
et al. [20]. Briefly, the centroids from 50 intrinsic genes were
compared between the training set and the cell lines analysed here
using Spearman’s rank correlation to predict the subtype on the
test set using PAM50 predictor bioclassifier R script with R2.13.0
(www.r-project.org) [20]. In a second step, Claudin-low subtype
prediction was performed as described by Prat et al. [21]. Briefly,
centroids for ‘‘claudin-low’’ or ‘‘others’’ were calculated on the
training set provided by Prat et al. [21] including different breast
cancer cell lines from the Neve et al. study [22]. For each novel
cell line to be classified, the Euclidean distance to the centroids
from the training set was calculated and the subtype assigned
according to the nearest centroid. Classification was performed
using R2.13.0 (www.r-project.org).
Luciferase Reporter Assay
56104 Py2T cells were plated in triplicate in a 24 well-plate.
One day after plating, cells were transfected with 800 ng reporter
and 5 ng Renilla encoding plasmids using Lipofectamine 2000.
Fresh growth medium was added after 5 hours of transfection
containing 2 ng/mL TGFb or not. After 2 days, cells were lysed
directly in plates using 16 passive lysis buffer (#E194, Promega)
and lysates were analyzed using the Dual-Luciferase Reporter
Assay System (#E1960, Promega) and a Berthold Luminometer
LB960. Measured luciferase values were normalized to internal
Renilla control. The Smad4 reporter was kindly provided by Dr.
P. ten Dijke (Leiden University; [23].
Cell Line Isolation
A piece (,200 mg) of freshly isolated tumor was transferred into
collection medium (DMEM supplemented with 10% FBS, 2 mM
glutamine, supplemented with Gentamycin (50 ug/mL)) and
minced into very small pieces using sterile technique with a scalpel.
Pieces were collected by rinsing with pre-digestion buffer (10 mM
HEPES pH 7.4, 142 mM NaCl, 0.67 mM KCl, 1 mM EDTA)
supplemented with Gentamycin (50 mg/mL)(G1397, Sigma-Al-
drich) and 16 Antibiotic-Antimycotic (15240-096, Invitrogen),
and transferred to a 15 mL Falcon tube. Pieces were predigested
in horizontal position at 200 rpm at 37uC for 30 min on a bacterial
shaker. Predigested tissue was pelleted by spinning at 9006g for
5 min, the supernatant was removed and the pellet was
resuspended in digestion mix (10 mM HEPES pH 7.4, 142 mM
NaCl, 0.67 mM KCl, 0.67 mM CaCl2, 20 mM Glucose, 1 mg/
mL Collagenase Type I, 0.1 mg/mL DNAseI) supplemented with
Gentamycin (50 mg/mL) and 16 Antibiotic-Antimycotic. The
tissue was digested by shaking in horizontal position at 200 rpm at
37uC for 30 min on a bacterial shaker. For final single cell
dissociation, tissue was pipetted up and down for 5 min using
a 1 mL pipette. Digested tissue was pelleted, washed twice in PBS
and plated into multiple wells of a 24 well-plate in normal growth
medium (DMEM supplemented with 10% FBS, 2 mM glutamine,
100 U penicillin and 0.2 mg/ml streptomycin). Growth medium
was exchanged the next day, and subsequently exchanged every
three to four days until epithelial cultures without Fibroblast
contamination emerged.
Immunofluorescence Staining of Cultured Cells
Cells were plated on glass coverslips and treated for the
indicated times with TGFb. The following steps were all done at
room temperature. After fixation using 4% paraformaldehyde/
PBS for 15 min, cells were permeabilized with 0.5% NP-40 for
5 min. Next, cells were blocked using 3% BSA, 0.01% TritonX-
100 in PBS for 20 min. Then, cells were incubated with the
indicated primary antibodies for 1 h followed by incubation with
the fluorochrome-labeled secondary antibody (Alexa FluorH,
Invitrogen) for 30 min at room temperature. Nuclei were stained
with 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) for
10 min. The coverslips were mounted (Fluorescent mounting
medium, Dako) on microscope slides and imaged with a conven-
tional immunofluorescence microscope (Leica DMI 4000) or
a confocal microscope (Zeiss LSM 510 Meta). Confocal stacks
were reconstructed with Imaris Software (Bitplane, Switzerland).
Immunoblotting
Cells were lysed in RIPA buffer (150 mM NaCl, 2 mM MgCl,
2 mM CaCl2, 0.5% NaDOC, 1% NP40, 0.1% SDS, 10%
Glycerol, 50 mM Tris pH 8.0) containing 2 mM Na3VO4,
10 mM NaF, 1 mM DTT, and a 1:200 dilution of stock protease
inhibitor cocktail for mammalian cells (Roche). Protein concen-
tration was determined using the BCA assay kit (Pierce). Equal
amounts of protein were diluted in SDS-PAGE loading buffer
(10% glycerol, 2% SDS, 65 mM Tris, 1 mg/100 ml bromophenol
blue, 1% b-mercaptoethanol) and resolved by SDS-PAGE.
Proteins were transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore) by semi-dry transfer, blocked with 5%
skim milk powder in TBS/0.05% Tween 20 and incubated with
the indicated antibodies. HRP conjugated secondary antibodies
were detected by chemiluminescence using a Fusion F67
chemiluminescence reader (Vilber Lourmat, France).
Retroviral Infection
A cDNA encoding EGFP was subcloned from pEGFP-N3
(Clontech) into the retroviral vector pBabe-hygro [24]. The
resulting plasmid pBH-EGFP was transfected into the retroviral
packaging cell line Plat-E (purchased from Cell Biolabs) [25]
using FugeneHD (Roche). One day after transfection, medium
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was exchanged and retroviral supernatant was produced for 2
days. Viral supernatant was filtered through 0.45 mm pores and
8 mg/mL Polybrene was added. Py2T cells were plated into 6-
well plates and were infected with viral supernatant one day
after plating. For infection, 2 mL supernatant was added per
well and plates were spun for 1 hour at 30uC at 10006g and
were subsequently incubated at 37uC with 5% CO2 in a tissue
culture incubator for 2 more hours. Viral supernatant was then
replaced by normal growth medium and one day later, selection
with 500 mg/mL Hygromycin B (Invitrogen) was performed for
5 consecutive days.
Lentiviral Infection
A cDNA encoding a human dominant-negative version of
TGFbRII (K277R) [26] (kindly provided by M. Oft, Targenics
Inc., San Francisco) was subcloned into the lentiviral expression
vector pLentiCMV (a kind gift from O. Pertz, University of Basel).
Lentiviral particles were produced by transfecting HEK293T cells
with the lentiviral expression vector pLentiTBRDN or empty
vector as a control, in combination with the helper vectors
pHDM-HGPM2, pHDM-Tat1b, pRC-CMV-RaII and the enve-
lope encoding vector pVSV using Fugene HD. After two days of
virus production, lentivirus-containing supernatants were har-
vested, filtered (0.45 mm) and added to target cells in the presence
of polybrene (8 mg/ml). Cells were spun for 1 hour at 30uC at
10006g and were subsequently incubated at 37uC with 5% CO2
in a tissue culture incubator for 2 more hours. Viral supernatant
was then replaced by normal growth medium and one day later,
selection with 5 mg/mL Puromycin (Sigma-Aldrich) was per-
formed for 3 consecutive days.
Boyden Chamber Migration and Invasion Assay
Cells pre-treated or not with TGFb were trypsinized, washed
once with PBS, and resuspended in growth medium containing
0.2% FBS and 2 ng/mL TGFb where appropriate. 2.56104 cells
in 500 mL were seeded into cell culture insert chambers
containing 8 mm pores (migration chambers: 353097, BD Falcon;
invasion chambers with ECM coating: 354483, BD Falcon) in
triplicate. Subsequently, the bottoms of chambers were filled with
700 mL of growth medium containing 20% FBS, and cells were
incubated in a tissue culture incubator at 37uC with 5% CO2.
After 24 hours, inserts were fixed with 4% PFA/PBS for 10 min.
Cells that had not crossed the membrane were removed with
a cotton swab, and cells on the bottom of the membrane were
stained with DAPI. Images of five fields per insert were taken
with a Leica DMI 4000 microscope and stained cells were
counted using an ImageJ software plugin developed in-house.
Subsequently, inserts were stained in crystal violet solution
(0.125% crystal violet, 20% MeOH) for 10 minutes, followed by
washing in a large volume of dH2O and drying over night.
Images of crystal violet stained inserts were taken with an
AxioVert microscope (Zeiss, Germany).
Scratch Wound Closure Assay
36105 untreated Py2T cells and 36105 Py2T cells treated with
TGFb for 13 days were seeded into 24-well plates with or without
TGFb. Normal growth medium was replaced by starving medium
containing 2% FBS with or without TGFb on the next day. After
starvation over night, a wound was scratched into confluent
monolayers and plates were transferred to an IncucyteTM live
imaging instrument (Essen BioScience).
3D Matrigel Culture and In-gel Immunofluorescence
Staining
Growth factor-reduced Matrigel (356230, BD) stock was thawed
on ice and diluted to 4 mg/mL protein with ice-cold, serum-free
growth medium. Cells were trypsinized, resuspended in ice-cold
normal growth medium and counted using a CASY cell counter
(Roche, Switzerland). A pellet of 2500 cells was resuspended in
10 mL of pre-diluted Matrigel and transferred to one well of a m-
slide angiogenesis microscopy slide (ibidi, Martinsried, Germany).
After an incubation of 20 min in a tissue culture incubator to allow
solidification of the gel, 50 mL of normal growth medium
containing or not 2 ng/mL TGFb was added to each well.
Growth medium was replenished every third day. After 6 days of
growth, structures were prepared for immunofluorescence analysis
directly in the matrix. Structures were fixed with 4% PFA/PBS for
10 min and washed with 20 mM glycine/PBS for 5 min. After
a second wash with PBS, cells were permeabilized and blocked
with IF buffer (0.2% TritonX-100/0.1% BSA/0.05% Tween20/
PBS) containing 10% goat serum. Samples were incubated with
primary antibodies diluted in IF buffer for 2 hours at room
temperature in a humid chamber. After 2 washes with IF buffer,
secondary antibodies diluted in IF buffer were incubated for 45
minutes, and nuclei were stained with DAPI solution for 20
minutes. After 2 final washes with IF buffer, samples were topped
with fluorescent mounting medium (Dako) and imaged with
a confocal microscope (LSM 510 Meta, Zeiss).
Soft Agar Colony Formation Assay
Cells were seeded into 6-well plates at 16104 cells per well in
0.35% agarose/DMEM complete growth medium onto a base
layer consisting of 0.5% agarose/DMEM complete growth
medium. Growth medium containing 2 ng/mL TGFb or not
was added on top of the agarose layers, and was replaced every
four days. After 10 days, viable colonies were stained with MTT
solution (Sigma-Aldrich) and were counted.
siRNA-mediated Knockdown
To achieve knockdown of Smad4, 10 nM final concentration of
siGENOME smart pool siRNAs (Dharmacon, M-040687-00-
0005) were used. A non-targeting pool was used as a control
(Dharmacon, D-001810-10-20). Two different, custom-designed
siRNAs against RhoA with the following sequences were used at
10 nM final concentration: siRhoA1 gaaggcagagauaugg-
caa(dT)(dT), siRhoA2 ugaagcaggagccgguaaa(dt)(dT). Negative
Universal Control Medium (45-2001, Invitrogen) served as
negative control. Reverse transfection of siRNAs was performed
with Lipofectamine RNAiMax reagent (Invitrogen) according to
the manufacturer’s instructions.
Orthotopic Tumor Cell Transplantation
Cells were trypsinized, washed twice and resuspended in ice-
cold PBS. Eight weeks old female BALB/c nude mice or FVB/N
mice were anaesthetized with isoflurane/oxygen and injected with
16106 Py2T cells in 100 mL PBS into mammary gland number 9.
Tumor volumes were calculated according to the formula
V = 0.5*D*d‘2, where D represents length and d represents width
of tumors measured by a digital caliper. Mice were sacrificed by
CO2 and tumors were isolated and further processed.
Histology and Immunostaining
For immunohistochemistry (IHC) and Haematoxylin & Eosin
(H&E) stainings, tumors were fixed at 4uC in 4% phosphate-
buffered paraformaldehyde (PFA) for 12 hours and then embed-
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ded in paraffin after ethanol/xylene dehydration. H&E staining
was performed as previously described [27,28]. For immunoflu-
orescence analysis of frozen sections, organs were fixed at 4uC in
4% PFA for 2 hours, and cryopreserved for 10 hours in 20%
sucrose in PBS prior to embedding in OCT freezing matrix. For
IHC stainings of PFA-fixed, paraffin-embedded specimens,
antigen epitopes were retrieved by boiling slides in 10 mM Na-
Citrate buffer (pH 6.0) in a PrestigeMedical Z2300 antigen
retriever. Stainings with mouse and rabbit antibodies were
performed using the Dako EnVision plus Kit (K4065) according
to the manufacturer’s recommendations. Cytokeratin 8/18
staining was performed using the Vectastain ABC kit (PK-6100
standard, Vector). Stainings were revealed by incubation with
biotinylated secondary antibodies and ABC Elite detection kit
using AEC substrate (all from Vector Laboratories) according to
the manufacturer’s instructions and counterstained using hema-
toxilin. Cryosections were cut 7 mm thick and dried for 309 prior
to rehydration in PBS. Slides were permeabilized with in PBS/
0.2% TritonX-100 and blocked for 30 min in PBS/5% normal
goat serum and then incubated with the primary antibody in
blocking buffer for 1 hour at room temperature. Immunofluores-
cence (IF) stainings were revealed by incubation with Alexa488 or
Alexa568 labeled secondary antibodies (Molecular Probes) and
nuclei were stained with DAPI (SIGMA). IHC stainings were
evaluated on an AxioVert microscope (Zeiss, Germany) and IF
stainings on a Leica DMI 4000 microscope (Leica Microsystems,
Germany).
Statistical Analysis
Statistical analysis and graphs were generated using the
GraphPad Prism software (GraphPad Software Inc, San Diego,
CA). All statistical analysis was performed by unpaired, two-sided
t-test.
Gene Expression Profiling Data
The raw data of gene expression profiling of Py2T cells in the
absence and presence of TGFb is publicly available at the
ArrayExpress Database (Accession number E-MEXP-3731, avail-
able at http://www.ebi.ac.uk/arrayexpress/).
Ethics Statement
Animal experiments were performed in strict accordance with
the guidelines of the Swiss Federal Veterinary Office (SFVO) and
the regulations of the Cantonal Veterinary Office of Basel-Stadt
(license numbers 1878, 1907, and 1908). During the whole course
of animal experiments, all efforts were made to minimize suffering.
Supporting Information
Figure S1 Canonical TGFb signaling in untreated versus
TGFb-treated Py2T cells. (A) Immunofluorescence staining for
total Smad2/3 (red) and phosphorylated (activated) pSmad3 (green).
Nuclei are visualized by DAPI staining. Scale bar, 20 mm. (B)
Transcriptional Smad activity was determined by a dual luciferase
reporter assay. Cells were transfected with a Smad4 luciferase
reporter containing a Smad-binding element (SBE-luc) or a control
plasmid lacking the SBE (luc), along with Renilla luciferase for
normalization. Relative luminescence units (RLU) are expressed as
mean +/2 S.E.M from 2 independent experiments.
(TIF)
Figure S2 Py2T tumors are characterized by a high
immune cell infiltration. Immunofluorescence staining of
a Py2T tumor for the leukocyte marker CD45 and the
macrophage marker F4/80. Images show a central region of
a tumor grown in nude mice as described in Figure 6. Scale bar,
50 mm.
(TIF)
Figure S3 Expression of a dominant-negative TGFb
receptor prevents EMT in vitro and does not signifi-
cantly affect tumor growth. (A) Py2T cells stably expressing
a dominant-negative TGFbRII (Py2T TBRDN) or cells trans-
duced with empty vector control were treated with TGFb (2 ng/
mL). To assess activation of canonical TGFb signaling and nuclear
accumulation of Smad proteins, cells were stained with an
antibody against Smad2/3. To evaluate the breakdown of cell
junctions downstream of TGFb signaling, cells were stained with
E-cadherin (adherens junctions) and ZO-1 (tight junctions). Scale
bars, 50 mm. (B) Tumor growth of Py2T TBRDN and control
cells (Experiment is described in Figure 6). n = 10 mice per group.
Data is presented as mean 6 S.E.M. Statistical values are
calculated by using an unpaired, two-tailed t-test. A p-value .0.05
was considered not significant.
(TIF)
Figure S4 Soft agar colony formation of epithelial and
mesenchymal Py2T cells. (A) Anchorage-independent growth
of epithelial Py2T and mesenchymal Py2T LT cells. Cells were
embedded in soft agar and supplemented with growth medium
containing TGFb (Py2T LT) or not (Py2T) and were allowed to
grow for 10 days. (B) Quantification of formed colonies. Data is
presented as mean 6 S.E.M. Statistical values are calculated by
using an unpaired, two-tailed t-test. ***p-value ,0.001.
(TIF)
Movie S1 Movie corresponding to Figure 4B: scratch
wound closure of untreated Py2T cells for 13 days.
(MOV)
Movie S2 Movie corresponding to Figure 4B: scratch
wound closure of Py2T cells treated with TGFb for 13
days.
(MOV)
Movie S3 Movie corresponding to Figure 4C: Live
imaging of Py2T cells grown on 2D tissue culture plastic.
(MOV)
Movie S4 Movie corresponding to Figure 4C: Live
imaging of Py2T LT cells grown on 2D tissue culture
plastic.
(MOV)
Movie S5 Movie corresponding to Figure 4D: Animation
of Py2T cells grown in extracellular matrix and stained
for either E-cadherin (red) and ZO-1 (green) or vimentin
(red) and fibronectin (green), respectively.
(MOV)
Movie S6 Movie corresponding to Figure 4D: Animation
of Py2T LT cells grown in extracellular matrix and
stained for either E-cadherin (red) and ZO-1 (green) or
vimentin (red) and fibronectin (green), respectively.
(MOV)
Table S1 List of genes that are significantly differen-
tially expressed by at least 2 fold between Py2T cells
(Py2T) and Py2T cells treated with TGFb for 20 days
(Py2T LT). Data is derived from two independent experiments.
(XLS)
Table S2 Sequences of RT-qPCR primers used.
(DOC)
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